Indonesia is hosting the 26th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers Network (DCVMN) in Bali. This meeting brings together 46 vaccine manufacturers, along with regulators and researchers.
The main agenda focuses on promoting innovation among vaccine producers in developing nations, strengthening research and development capacity, and building a resilient and equitable global health system.
DCVMN CEO Rajinder Suri stated that in recent years, there has been remarkable growth among vaccine manufacturers in developing countries, including their efforts to produce world-class vaccines.
“During the Covid-19 pandemic, vaccine manufacturers from developing countries produced over 9.8 billion doses of Covid-19 vaccines out of a global total of 15.9 billion. That means 62 percent of global production came from developing country manufacturers,” he said.
Redefining Vaccines
Indonesia’s Minister of Health, Budi Gunadi Sadikin, in his welcome video, expressed that it is a great honor for Indonesia to host this event. He noted that DCVMN is redefining global vaccine manufacturing by expanding capacity, adopting new technologies, and strengthening partnerships.
This 26th DCVMN annual meeting carries the theme “Advancing Innovation and Building a Resilient Vaccine Ecosystem for a Safer World.” The forum serves as a crucial moment to enhance the capabilities of vaccine producers from developing countries. It also highlights achievements and partnership improvements aimed at strengthening sustainable vaccine supply.
DCVMN was established in 2000 and consists of 46 vaccine manufacturers from 17 developing countries. The network focuses on equitable access to high-quality vaccines. Together with global health organizations, DCVMN works to ensure that every country has the ability to produce and provide affordable vaccines.
The DCVMN forum is vital for sharing perspectives and finding solutions to global vaccine resilience. It brings together manufacturers, international health institutions, and donor agencies to build a robust vaccine ecosystem.